Cargando…

Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6

Aim: Tramadol is widely used to treat acute, chronic, and neuropathic pain. Its primary active metabolite, O-desmethyltramadol (M1), is mainly responsible for its µ-opioid receptor-related analgesic effect. Tramadol is metabolized to M1 mainly by the cytochrome P450 (CYP) 2D6 enzyme, and to other me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Joomi, Yoo, Hee-Doo, Bae, Jung-Woo, Lee, Sooyeun, Shin, Kwang-Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537040/ https://www.ncbi.nlm.nih.gov/pubmed/31213765 http://dx.doi.org/10.2147/DDDT.S199574

Ejemplares similares

Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2019)

Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats
por: Bao, Su-su, et al.
Publicado: (2023)

Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients
por: Al-Qurain, Aymen A., et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition
por: Long, Tao, et al.
Publicado: (2021)

Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia
por: Lee, Joomi, et al.
Publicado: (2021)

Inhibition by O-desmethyltramadol of glutamatergic excitatory transmission in adult rat spinal substantia gelatinosa neurons
por: Koga, Akiko, et al.
Publicado: (2019)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers
por: Jung, Eben, et al.
Publicado: (2018)

Postmenstrual age and CYP2D6 polymorphisms determine urinary tramadol O-demethylation excretion in critically ill neonates and infants
por: Allegaert, K, et al.
Publicado: (2008)

Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
por: Lee, Jin Sol, et al.
Publicado: (2013)

Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
por: Lee, Hye Ja, et al.
Publicado: (2011)

Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol
por: Rodieux, Frédérique, et al.
Publicado: (2023)

Gender Dependency in Streoselective Pharmacokinetics of Tramadol and Its Phase I Metabolites in Relation to CYP2D6 Phenotype in Iranian Population
por: Hosseinzadeh Ardakani, Yalda, et al.
Publicado: (2018)

Caffeine Induces High Expression of cyp-35A Family Genes and Inhibits the Early Larval Development in Caenorhabditis elegans
por: Min, Hyemin, et al.
Publicado: (2015)

Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
por: Kim, Hyun Chul, et al.
Publicado: (2022)

A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans
por: Ryu, S, et al.
Publicado: (2017)

Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling
por: Ohk, Boram, et al.
Publicado: (2022)

Analgesic Effects of Tramadol During Panretinal Photocoagulation
por: Ko, Byoung-Woo, et al.
Publicado: (2009)

Study of the pharmacokinetic changes of Tramadol in diabetic rats
por: Lavasani, Hoda, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics Evaluation of Tramadol in Thermoreversible Gels
por: Papini, Juliana Zampoli Boava, et al.
Publicado: (2017)

Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects
por: Ma, Hui, et al.
Publicado: (2018)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011)

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
por: Park, Hyung Seok, et al.
Publicado: (2011)

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
por: Chan, Sze Wa, et al.
Publicado: (2021)

The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs
por: Trenaman, Shanna C., et al.
Publicado: (2021)

An Investigation of O-Demethyl Tramadol/Tramadol Ratio for Cytochrome P450 2D6 Phenotyping: The CYTRAM Study
por: De La Gastine, Blandine, et al.
Publicado: (2022)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
por: Kim, K-p, et al.
Publicado: (2011)

Negative myoclonus associated with tramadol use
por: Bae, Seong Yoon, et al.
Publicado: (2020)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Comparison of pharmacokinetics of tramadol between young and middle-aged dogs
por: ITAMI, Takaharu, et al.
Publicado: (2016)

The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
por: Pavlovic, Dimitrije, et al.
Publicado: (2020)

Commentary on: “study of the pharmacokinetic changes of tramadol in diabetic rats” is the handicapped renal pathway in DMIS contributing for the increased bioavailability of tramadol?
por: Srinivas, Nuggehally R
Publicado: (2013)

Uptake/Efflux Transport of Tramadol Enantiomers and O-Desmethyl-Tramadol: Focus on P-Glycoprotein
por: Kanaan, Mouna, et al.
Publicado: (2009)

Dependence Potential of Tramadol: Behavioral Pharmacology in Rodents
por: Cha, Hye Jin, et al.
Publicado: (2014)

Genetic Polymorphism of CYP2D6 and Clomiphene Concentrations in Infertile Patients with Ovulatory Dysfunction Treated with Clomiphene Citrate
por: Ji, Misuk, et al.
Publicado: (2016)

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
por: Kim, Se-Hyung, et al.
Publicado: (2018)

Comparing the Pharmacokinetics of 2 Novel Intravenous Tramadol Dosing Regimens to Oral Tramadol: A Randomized 3‐Arm Crossover Study
por: Lu, Lucy, et al.
Publicado: (2019)

Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A
por: Rafehi, Muhammad, et al.
Publicado: (2019)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
por: Grzegorzewski, Jan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vn3aj75aq4c9f0h6iuhichhmor